Ethanolamine Oleate
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Ethanolamine Oleate
- Ethanolamine Oleate: From Sclerotherapy of Oesophageal Varices to Oesophageal Disease
Ethanolamine Oleate: From Sclerotherapy of Oesophageal Varices to Oesophageal Disease
One-Sentence Summary
Ethanolamine oleate is a sclerosing agent historically administered by endoscopic injection to control bleeding from oesophageal and gastric varices, though it currently holds no UK marketing authorisation. Of the ten candidate indications generated by TxGNN, only oesophageal disease (i.e., variceal sclerotherapy) is backed by meaningful evidence — 3 clinical trials and 20 publications, including several randomised controlled trials — while the model’s higher-scoring “novel” predictions (e.g., non-syndromic oesophageal malformation, immune thrombocytopenia) were reviewed in the evidence pack and found to have no plausible mechanistic or clinical support.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this evidence pack (no UK licences, no original_indications entries); the literature consistently documents ethanolamine oleate as a sclerosing agent for bleeding oesophageal/gastric varices |
| Predicted New Indication | Oesophageal disease (endoscopic variceal sclerotherapy) — a confirmatory signal for an already-established use, not a genuinely novel indication |
| TxGNN Prediction Score | 95.98% |
| Evidence Level | L1 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
A note on the model’s top-ranked candidates: TxGNN’s highest raw scores went to non-syndromic oesophageal malformation (98.27%), primary platelet release disorder (97.97%), immune thrombocytopenia (97.81%), pseudo-von Willebrand disease (97.76%) and Glanzmann thrombasthenia (97.53%). All five were reviewed and returned no clinical trials, no literature, and no plausible mechanistic link — the evidence pack itself flags these as graph-proximity artefacts rather than real signals, and each carries a “Hold” recommendation at evidence level L5. They are not carried forward in this report.
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available for ethanolamine oleate in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, ethanolamine oleate is a classic chemical sclerosant: intravariceal injection induces local chemical damage to the venous endothelium, triggering thrombosis and subsequent fibrosis that obliterates the varix. This mechanism has underpinned endoscopic injection sclerotherapy (EIS) for decades.
Because the “new” indication — oesophageal disease — sits in the same organ system and pathophysiological space (portal hypertension leading to oesophageal/gastric variceal bleeding) as the drug’s known clinical use, this is best understood as the evidence base re-confirming an established use rather than a genuine repurposing opportunity. The clinical trial and literature evidence below directly compares ethanolamine oleate against other sclerosants (polidocanol, absolute ethanol, N-butyl-2-cyanoacrylate) and against newer techniques (band ligation, balloon-occluded retrograde transvenous obliteration), all within variceal bleeding management.
By contrast, the mechanistic rationale for the higher-scoring novel candidates does not hold up: structural congenital oesophageal malformations are anatomical defects unrelated to a chemical sclerosant’s mode of action, and the platelet/coagulation disorders (Scott syndrome, Glanzmann thrombasthenia, pseudo-von Willebrand disease) have no established connection to endothelial sclerosis. The one partial exception — immune thrombocytopenia — has a single mechanistic paper on a related sclerosant (sodium morrhuate) showing granulocyte activation and endothelial/erythrocyte damage, but this is indirect, does not involve ethanolamine oleate itself, and does not establish a therapeutic (rather than adverse) effect.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00799851 | Phase 4 | Completed | 38 | Randomised comparison of variceal band ligation vs. cyanoacrylate injection for oesophageal varices in advanced liver disease |
| NCT02646202 | Phase 3 | Unknown | 90 | Sclerotherapy plus ligation (“scleroligation”) assessed as a safe, effective technique for eradicating gastro-oesophageal varices |
| NCT01931826 | N/A | Completed | 54 | Endoscopic therapy (alone or combined with surgery) for bleeding oesophageal varices due to schistosomal portal hypertension |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3552917 | 1987 | RCT | Hepato-gastroenterology | Ethanolamine oleate found superior to polidocanol for endoscopic injection sclerotherapy of oesophageal varices |
| 10805844 | 2000 | RCT | Gastrointestinal Endoscopy | Absolute ethanol and 5% ethanolamine oleate show comparable efficacy and safety as sclerosants for oesophageal varices |
| 3229387 | 1988 | RCT | Endoscopy | Prospective trial comparing large vs. small injection volumes of 5% ethanolamine oleate in cirrhotic patients with oesophageal varices |
| 2693076 | 1989 | RCT | Endoscopy | Prospective randomised trial: ethanolamine oleate achieved higher variceal eradication (81%) than polidocanol (64%), with a significant difference in rebleeding rates |
| 1483669 | 1992 | RCT | Hepato-gastroenterology | Randomised comparison of ethanolamine oleate alone vs. combined with polidocanol; no major complications in either group |
| 2181708 | 1990 | Review | Surgical Clinics of North America | Overview of endoscopic sclerotherapy techniques, favouring intravariceal/paravariceal ethanolamine oleate injection for acute and long-term variceal bleeding control |
| 30170340 | 2019 | Review | Journal of Gastroenterology and Hepatology | Reviews development of balloon-occluded retrograde transvenous obliteration (BRTO), noting ethanolamine oleate as the original sclerosant used since 1994 |
| 37095235 | 2023 | Cohort | Surgical Endoscopy | Endoscopic injection sclerotherapy with N-butyl-2-cyanoacrylate/ethanolamine oleate found equivalent to BRTO for preventing gastric variceal rebleeding |
| 7588349 | 1995 | Cohort | Endoscopy | Combined N-butyl-2-cyanoacrylate and 5% ethanolamine oleate assessed for managing bleeding oesophagogastric varices |
| 29264640 | 2018 | Cohort | Cardiovascular and Interventional Radiology | Long-term BRTO outcomes: ethanolamine oleate compared with sodium tetradecyl sulfate for gastric varices |
UK Market Information
No UK marketing authorisation (MHRA) records were identified in this evidence pack — ethanolamine oleate currently has 0 licences on file and is classified as Not marketed in the United Kingdom. Any clinical use would require sourcing via the unlicensed medicines (“specials”) route or named-patient import, with corresponding MHRA notification and enhanced pharmacovigilance obligations.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple randomised controlled trials and clinical trials support ethanolamine oleate’s efficacy as a variceal sclerosant, giving this indication an L1 evidence level — but the drug has no current UK marketing authorisation, and mechanism-of-action and safety label data are entirely absent from this evidence pack, so guardrails around sourcing and safety monitoring are essential before clinical use.
To proceed, the following is needed:
- Detailed mechanism of action (MOA) data from DrugBank or the manufacturer
- SmPC-level safety data (warnings, contraindications, drug interactions) — currently a Blocking data gap
- Confirmation of a UK unlicensed-medicines supply route (import licence/specials manufacturer) given zero UK marketing authorisations
- A formal decision to disregard the model’s higher-scoring but mechanistically implausible predictions (oesophageal malformation, platelet/coagulation disorders), which lack any supporting evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.